Search | MakeMyFriends

Sanjay Kokate added blog Health
2026-01-29 07:58:28 -

Diabetes Drug Market Growing Strongly with Rising Global Diabetes Prevalence and Novel Therapeutic Launches
The 2025 Breakthrough in Diabetes Drug Development In 2025, diabetes drug innovation is accelerating through AI-powered precision medicine. With type 2 diabetes affecting over 500 million people globally, B2B healthcare stakeholders are leveraging AI to optimize drug discovery, personalize treatment, and reduce time-to-market for novel therapies. AI Applications in Diabetes Drug Response...

0 Comments 0 Shares 113 Views 0 Reviews

Please log in to like, share and comment!
Sharvari Kumbhare added blog Other
2026-04-17 07:48:02 -

Europe Empagliflozin Drug Market Growth Driven by Rising Diabetes Burden and Expanding Cardiorenal Indications to 2032
According to a new report from Intel Market Research, the Europe Empagliflozin Drug market was valued at USD 4,450 million in 2024 and is projected to grow from USD 5,125 million in 2025 to USD 12,585 million by 2032, growing at a robust CAGR of 17.0% during the forecast period (2025–2032). This growth is propelled by the rising diabetes prevalence with over 61 million adults affected in...

0 Comments 0 Shares 24 Views 0 Reviews

Please log in to like, share and comment!
Kiran Aggarwal added blog Other
2026-04-07 13:19:18 -

Smart Insulin Pens and Pumps Market Driven by Rising Diabetes Prevalence and Demand for Advanced Drug Delivery Solutions, Forecast to 2033
Smart Insulin Pens and Pumps Market Outlook Straits Research, a leading provider of business intelligence, research, and advisory services, has released its latest report on the Smart Insulin Pens and Pumps Market, highlighting strong growth driven by the increasing global burden of diabetes and the growing adoption of advanced diabetes management technologies. According to the report, the...

0 Comments 0 Shares 137 Views 0 Reviews

Please log in to like, share and comment!
Pratiksha Dhote added blog Health
2026-04-14 11:58:18 -

GLP‑1 receptor agonists: the weight‑loss wonder drugs that started as diabetes meds
Ozempic, Wegovy, Mounjaro — you've heard the hype. These GLP‑1 receptor agonists were developed for diabetes, but they cause dramatic weight loss. The diabetes drug market research shows that GLP‑1s are the fastest‑growing drug class, with a CAGR above 10%. Why? Because they not only lower blood sugar but also reduce appetite, slow stomach emptying, and even protect the...

0 Comments 0 Shares 25 Views 0 Reviews

Please log in to like, share and comment!